持久性癌细胞的脂质变化驱动了增强的铁亡敏感性
Eduard Reznik1, Fereshteh Zandkarimi2,3, Joleen M Csuka2
1Department of Biological Sciences, Columbia University, New York, NY 10027, USA.
概括
持久性癌细胞 (PSs) 由于特定的脂质组变化而表现出更高的铁灭敏感性. 这些与线粒体活动相关的变化对于耐药癌细胞的生存至关重要.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 持久性癌细胞 (PSs) 是耐药的细胞,通过可逆的染色质介导变化在治疗中存活.
- PSs与最小残留疾病和癌症复发有关.
- PSs对ferroptosis表现出敏感性,这是针对耐药癌症的关键漏洞.
研究的目的:
- 调查持久性癌细胞 (PSs) 的脂质特征和它们与铁灭敏感性的关系.
- 确定药物耐药癌细胞中潜在的生物标志物和铁灭敏感性的驱动因素.
- 探索线粒体在PSs的铁灭敏感性中的作用.
主要方法:
- 从肺癌PC9细胞中提取PS细胞 (PSPC9),并进行转录和脂质分析.
- 将逆转的PSPC9细胞转化为耐铁灭的状态 (PC9PS -> PC9),以评估脂质变化.
- 产生了额外的PS样模型 (PSLNCaP,PSHT1080) 并进行了脂管学和线粒体消除试验.
主要成果:
- 在PSPC9细胞中,脂质和糖代谢基因的表达增强,二PUFA脂 (diPUFA-PL) 和多不和自由脂肪酸 (PUFA FFAs) 的增加.
- 在PSPC9细胞恢复到父细胞状态时,脂质样本恢复了.
- 类似PS的模型 (LNCaP,HT1080) 表现出PS的特征,包括增强的铁灭菌敏感性和特定的脂质配置文件.
- 线粒体消除部分降低了ferroptosis敏感性,并改变了PS脂质谱.
结论:
- 脂质变化,特别是涉及diPUFA-PL和PUFA FFAs的变化,是对铁灭敏感的持续性癌细胞的特征.
- 线粒体活动在调节耐药性持续性癌细胞的铁灭敏感性方面发挥着关键作用.
- 针对这些依赖于线粒体的脂质体变化是克服癌症耐药性的潜在策略.
相关概念视频
Necrosis
6.2K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.2K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K

